Cadila Healthcare Gains On Agreement To Market Black Fungus Drug

0
28


AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India.

Shares of Cadila Healthcare rose as much as 1.72 per cent to hit an intraday high of Rs 633.20 after it informed exchanges that Zydus Cadila has entered into an agreement with TLC, a Taiwan-based clinical-stage, specialty pharmaceutical company for marketing Mucormycosis or Black Fungus drug in the country.

Zydus Cadila signed a license supply and commercialization agreement to commercialize AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India.

“AmphoTLC is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India,” Cadila Healthcare said in a press release.

“AmphoTLC is the first and only complex generic drug to have achieved bioequivalence to Gilead’s AmBisome, proving its sameness to the safest form of amphotericin B in the world. With the surge of infections in India in the recent days AmphoTLC will address the country’s acute liposomal amphotericin B shortage,” Cadila Healthcare added.

Mucormycosis is a serious fungal infection also known as black fungus, and COVID Associated Mucormycosis is a life-threatening form of mucormycosis which has emerged as a post-COVID complication, infecting about 30 per cent of COVID patients who are diabetic or otherwise immunocompromised. If progression of the infection is not treated early, over 60% of patients could die, Cadila Healthcare said.

AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis. The drug is approved in Taiwan and has been manufactured and sold by Yung Shin Pharmaceutical Industrial Co. (YSP) for several years. The approval of AmphoTLC in India follows the conduct of comprehensive due diligence by regulators in India based on the numerous years of development TLC has dedicated as well as its quality performance in the developed markets.

The steep increase in price and the financial burden it brings is forcing patients to opt for conventional amphotericin B, which is known for its nephrotoxicity, with many patients having to discontinue usage due to renal toxicities, the Ahmedabad-based drug maker added.

As of 1:47 pm, Cadila Healthcare shares traded 0.6 per cent higher at Rs 626, in-line with Sensex which was up 0.6 per cent.



Source link